194 related articles for article (PubMed ID: 17184102)
1. Low and ultra low-dose estrogen therapy for climacteric symptom control--preliminary report.
Carranza-Lira S; Gooch AL; Velasco-Díaz G; Solano J; Arzola-Paniagua A
Int J Fertil Womens Med; 2006; 51(4):171-5. PubMed ID: 17184102
[TBL] [Abstract][Full Text] [Related]
2. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.
Carranza-Lira S; Gooch AL; Saldivar N; Osterwalder MS
Int J Fertil Womens Med; 2007; 52(2-3):93-6. PubMed ID: 18320867
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
4. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Vacca F; Genazzani AR
Maturitas; 2005 Feb; 50(2):91-7. PubMed ID: 15653005
[TBL] [Abstract][Full Text] [Related]
5. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome.
Simon JA; Stevens RE; Ayres SA; Phelps KV
Climacteric; 2001 Mar; 4(1):19-27. PubMed ID: 11379374
[TBL] [Abstract][Full Text] [Related]
6. Applied relaxation and oral estradiol treatment of vasomotor symptoms in postmenopausal women.
Nedstrand E; Wijma K; Wyon Y; Hammar M
Maturitas; 2005 Jun; 51(2):154-62. PubMed ID: 15917156
[TBL] [Abstract][Full Text] [Related]
7. Changes in symptoms, lipid and hormone levels after the administration of a cream with phytoestrogens in the Climacteric--preliminary report.
Carranza-Lira S; Barahona OF; Ramos D; Herrera J; Olivares-Segura A; Cardoso G; Posadas-Romero C
Int J Fertil Womens Med; 2001; 46(6):296-9. PubMed ID: 11795688
[TBL] [Abstract][Full Text] [Related]
8. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
9. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
Chandeying V; Sangthawan M
J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
[TBL] [Abstract][Full Text] [Related]
10. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
Cieraad D; Conradt C; Jesinger D; Bakowski M
Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
[TBL] [Abstract][Full Text] [Related]
11. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
12. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study.
Kaari C; Haidar MA; Júnior JM; Nunes MG; Quadros LG; Kemp C; Stavale JN; Baracat EC
Maturitas; 2006 Jan; 53(1):49-58. PubMed ID: 16257151
[TBL] [Abstract][Full Text] [Related]
14. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.
Limpaphayom KK; Darmasetiawan MS; Hussain RI; Burriss SW; Holinka CF; Ausmanas MK
Climacteric; 2006 Jun; 9(3):204-14. PubMed ID: 16766434
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Kupperman's index with estrogen and androgen levels, according to weight and body fat distribution in postmenopausal women from Mexico City.
Carranza-Lira S; Velasco Díaz G; Olivares A; Chán Verdugo R; Herrera J
Int J Fertil Womens Med; 2006; 51(2):83-8. PubMed ID: 16881384
[TBL] [Abstract][Full Text] [Related]
16. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
Stevenson JC; Durand G; Kahler E; Pertyński T
Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
[TBL] [Abstract][Full Text] [Related]
17. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial.
Liu JH; Reape KZ; Hait HI
Obstet Gynecol; 2012 Jan; 119(1):78-84. PubMed ID: 22183214
[TBL] [Abstract][Full Text] [Related]
18. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens.
Utian WH; Lederman SA; Williams BM; Vega RY; Koltun WD; Leonard TW
Obstet Gynecol; 2004 Feb; 103(2):245-53. PubMed ID: 14754691
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
Speroff L; Haney AF; Gilbert RD; Ellman H;
Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
[TBL] [Abstract][Full Text] [Related]
20. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
Simon JA; Reape KZ; Wininger S; Hait H
Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
